Activin and Inhibin

LT052 is a highly selective BET BD1 inhibitor with an IC 50 of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC 50 =12.130 μM). LT052 has anti-inflammatory activity and can be used for acute gout

LTV-1 is a potent lymphoid tyrosine phosphatase ( LYP ) inhibitor in T cells with an IC 50 of 508 nM. LTV-1 has the potential for autoimmunity treatmentIn VitroLTV-1 (1.25-40 μM) has no notable effect on cell viability (metabolic rate assay), even

LTV-1 is a potent lymphoid tyrosine phosphatase ( LYP ) inhibitor in T cells with an IC 50 of 508 nM. LTV-1 has the potential for autoimmunity treatmentIn VitroLTV-1 (1.25-40 μM) has no notable effect on cell viability (metabolic rate assay), even

LTV-1 is a potent lymphoid tyrosine phosphatase ( LYP ) inhibitor in T cells with an IC 50 of 508 nM. LTV-1 has the potential for autoimmunity treatmentIn VitroLTV-1 (1.25-40 μM) has no notable effect on cell viability (metabolic rate assay), even

LTV-1 is a potent lymphoid tyrosine phosphatase ( LYP ) inhibitor in T cells with an IC 50 of 508 nM. LTV-1 has the potential for autoimmunity treatmentIn VitroLTV-1 (1.25-40 μM) has no notable effect on cell viability (metabolic rate assay), even

LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1

LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1

LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1

LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1

LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1

LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1

Lu AF27139 is a potent, selective, and orally active antagonist of P2X7 receptor ( IC 50 s of 12 and 2.4 nM for human and rat, K i s of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant